RNS Number : 5235T
Shield Therapeutics PLC
26 March 2021

Shield Therapeutics plc
("Shield Therapeutics" or the "Company")

Study demonstrates real-world effectiveness of ferric maltol

Clinical collaborators publish results from FRESH study in BMJ Open Gastroenterology

London, UK, 26 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), notes the recent publication in *BMJ Open Gastroenterology*, titled: "*Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK.*"

The study details the positive results from a real-world study using ferric maltol to assess clinical characteristics and outcomes of patients with inflammatory bowel disease (IBD) receiving ferric maltol for iron-deficiency anaemia in the UK (FRESH Study).

The observational, multicentre study, retrospective cohort study included adults with IBD and iron-deficiency anaemia (IDA) and who also had serum ferritin levels below 30 µg/L or transferrin saturation below 20%, who received ferric maltol. The study concluded that ferric maltol increases haemoglobin and iron indices and is generally well tolerated in patients with IBD and IDA treated in clinical practice. These real-world data confirm the favourable benefit/risk balance findings from randomised control trials.

For further information, please contact:

Shield Therapeutics plc +44 (0) 191 511 8500
Tim Watts (CEO)

Peel Hunt LLP - **Nominated Adviser and Joint Broker** +44 (0) 20 7148 8900
James Steel / Christopher Golden

finnCap Ltd - Joint Broker +44 (0) 20 7220 0500
Geoff Nash / Alice Lane / Matthew Radley

Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Lianne Cawthorne or shield@walbrookpr.com

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAPPUMWWUPGGPA